# US 2024/0198256 A1 · Method for High Purity High Throughput Isolation of Extracellular Vesicles Using Size Exclusion Chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0198256 A1
- Document ID: US20240198256A1
- Status: Published application
- Kind: A1
- Application number: 18/540,481
- Filed: 2023-12-14
- Published: 2024-06-20
- Earliest claimed: 2022-12-14
- Assignees: Northeastern University
- Applicants: Northeastern University
- Inventors: Alexander IVANOV; Alan Zimmerman
- Web page: https://patentgrep.com/patent/US20240198256A1

## CPC

- B01D 15/327: {with hydrophobic interaction}
- B01D 15/3847: {Multimodal interactions}
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 7/02: Recovery or purification
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present technology provides straightforward, reproducible, scalable, and efficient multimode chromatography-based methods for the effective isolation and/or purification of nanoparticulate biomaterials from mixtures of biomaterials. The methods can be used to isolate and purify extracellular vesicles and other nanoparticulate biomaterials from plasma and other sources to provide high purity products. The methods can be used to diagnose medical conditions and to prepare pharmaceutical products.

## Claims

### Claim 1

A method of isolating and/or purifying a nanoparticulate biomaterial, the method comprising the steps of:
(a) providing a sample comprising the nanoparticulate biomaterial and a multimodal chromatography resin, wherein the sample comprises said nanoparticulate biomaterial suspended in an aqueous liquid; and
(b) contacting the sample with the multimodal chromatography resin for an incubation period, and;
(c) separating the nanoparticulate biomaterial from the multimodal chromatography resin, whereby the nanoparticulate biomaterial is isolated and/or purified from other components of the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nanoparticulate biomaterial is selected from the group consisting of extracellular vesicles and particles (EVP), viruses, viral vectors, pseudoviruses, virus-like particles, polymeric nanoparticles, lipidic nanoparticles, artificial lipid membrane vesicles, and nanoparticulate drug carriers.

### Claim 3 (depends on 2)

The method of claim 2, wherein the nanoparticulate biomaterial is EVP comprising exomeres, supermeres, exosomes, and/or microvesicles.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nanoparticulate biomaterial has an average particle size in a range from about 50 nm to about 100 nm, or from about 100 nm to about 150 nm, or from about 100 nm to about 200 nm, about 200 nm or less, from about 200 nm to about 1000 nm, or more than 1000 nm.

### Claim 5 (depends on 1)

The method of claim 1, wherein the sample is a biological fluid; plasma;
interstitial fluid; cerebrospinal fluid; saliva; cell culture medium; homogenized biological cells, tissue, or extracellular matrix; a pharmaceutical composition; a vaccine composition; or aerosol droplets or breath condensate; tear fluid; tissue aspirate, sputum; nasal fluid; lavage; artificially prepared emulsion, micelles, lipid droplets, or liposomes; or a tissue homogenate from a mammal, plant, mushroom, or alga.

### Claim 6 (depends on 1)

The method of claim 1, wherein the multimodal chromatography resin comprises porous resin particles having one or more functional groups selectively disposed inside the porous resin particles.

### Claim 7 (depends on 6)

The method of claim 6, wherein the functional groups are selected from ionic groups, hydrophobic groups, hydrophilic groups, amphiphilic groups, polar uncharged groups, non-polar groups, affinity-based groups, octylamine, and N-benzyl, N-methyl ethanolamine.

### Claim 8 (depends on 6)

The method of claim 6, wherein the multimodal chromatography resin is capable of separating said nanoparticulate biomaterial from other components of the sample by at least a first mode and a second mode, wherein the first mode is size exclusion chromatography, and wherein the second mode is different from size exclusion chromatography.

### Claim 9 (depends on 8)

The method of claim 8, wherein the second mode is ion exchange chromatography, hydrophobic interaction chromatography, reversed phase chromatography, or affinity chromatography.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ion exchange chromatography is anion exchange or cation exchange chromatography.

### Claim 11 (depends on 6)

The method of claim 6, wherein the porous resin particles comprise pores having an average size of about 19 nm, about 50 nm, or about 72 nm.

### Claim 12 (depends on 1)

The method of claim 1, wherein the step of contacting is performed using a suspension of particles of said multimodal chromatography resin in an aqueous medium.

### Claim 13 (depends on 12)

The method of claim 12, wherein the suspension is mixed during the incubation period.

### Claim 14 (depends on 1)

The method of claim 1, wherein the incubation period is long enough to attain binding equilibrium of undesired components of the sample with the functional groups inside the porous resin particles of the multimodal chromatography resin.

### Claim 15 (depends on 12)

The method of claim 12, wherein the step of separating includes centrifugation or filtration of the suspension and harvesting the isolated and/or purified nanoparticulate biomaterial from the supernatant or filtrate.

### Claim 16 (depends on 1)

The method of claim 1, wherein the step of contacting is performed using a bed of said multimodal chromatography resin, the bed disposed in a chromatography column, and wherein the step of separating is performed by eluting fractions from the column, some of said fractions comprising the isolated and/or purified nanoparticulate biomaterial.

### Claim 17 (depends on 16)

The method of claim 16, wherein the chromatography column is a sandwich column comprising the bed of said multimodal chromatography resin and a second bed comprising a second chromatography resin, wherein the multimodal chromatography resin and the second chromatography resin are capable of different modes of separation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the multimodal chromatography resin performs size exclusion and anion exchange and the second chromatography resin performs size exclusion.

### Claim 19 (depends on 17)

The method of claim 17, wherein the multimodal chromatography resin is disposed above the second chromatography resin in the column.

### Claim 20 (depends on 16)

The method of claim 16, wherein the chromatography column is a multilayer column comprising the bed (layer) of said multimodal chromatography resin and at least two other beds (layers) comprising a other chromatography resins, wherein the multimodal chromatography resin and the other chromatography resins are capable of different two or more modes of separation.

### Claim 21 (depends on 1)

The method of claim 1, wherein the method does not comprise ultracentrifugation.

### Claim 22 (depends on 1)

The method of claim 1, wherein the nanoparticulate biomaterial is separated from other biomaterial present in the sample.

### Claim 23 (depends on 22)

The method of claim 22, wherein the other biomaterial is protein or other particulate material.

### Claim 24 (depends on 1)

The method of claim 1, wherein the nanoparticulate biomaterial is fractionated to yield one or more isolated and/or purified subpopulations.

### Claim 25 (depends on 24)

The method of claim 24, wherein the nanoparticulate biomaterial that is isolated and/or purified is EVP, and the other biomaterial is plasma protein, albumin, immunoglobulin, alpha-2 macroglobulin, apolipoprotein B100, apolipoprotein A1, haptoglobin, serotransferrin, and/or alpha-1-antitrypsin.

### Claim 26 (depends on 23)

The method of claim 23, wherein the isolated and/or purified EVP are enriched in CD9, annexin A2, and/or 14-3-3 zeta/delta compared to the sample.

### Claim 27 (depends on 1)

The method of claim 1, further comprising analyzing the separated nanoparticulate biomaterial using a method selected from TEM, BCA, WB, TRPS, nFCM, or nLC-MS/MS.

### Claim 28 (depends on 1)

A chromatography column configured for performing the method of claim 1.

### Claim 29 (depends on 28)

The chromatography column of claim 28, comprising a multimodal chromatography resin and a size exclusion chromatography resin, and optionally one or more other chromatography resins, wherein the chromatography column is configured as a sandwich column or a multilayered column.

### Claim 30 (depends on 1)

A kit for isolating and/or purifying a nanoparticulate biomaterial, the kit comprising:
a multimodal chromatography resin or a column comprising a multimodal chromatography resin; and
instructions for carrying out the method of claim 1.

### Claim 31 (depends on 1)

A method of diagnosing a disease or medical condition, the method comprising the steps of:
(a) providing a sample from a subject suspected of having the disease or medical condition and a chromatography column comprising a multimodal chromatography resin and a size exclusion chromatography resin, and optionally one or more other chromatography resins, wherein the chromatography column is configured as a sandwich column or a multilayered column;
(b) performing the method of claim 1, whereby an isolated and/or purified nanoparticulate biomaterial is obtained; and
(c) analyzing the isolated and/or purified nanoparticulate biomaterial to diagnose the disease or medical condition.

### Claim 32 (depends on 31)

The method of claim 31, further comprising:
(d) treating the disease or medical condition.
